Welcome to our dedicated page for CDT Equity news (Ticker: CDT), a resource for investors and traders seeking the latest updates and insights on CDT Equity stock.
CDT Equity Inc. develops and repositions biopharmaceutical assets through a data-driven model that combines licensed clinical compounds, solid-form chemistry, cocrystal intellectual property and out-licensing. News about CDT commonly covers its AZD1656, AZD5658 and AZD5904 assets, patent filings, therapeutic-indication analysis, and programs spanning autoimmune disorders, idiopathic male infertility, dermatology, oncology, rare disease and animal health.
Company updates also include CDT's 20% equity interest in Sarborg Limited, whose Signature Agent, Multi-Agent and Signature Intelligence platforms are used for disease mapping and therapeutic-opportunity identification. Other recurring items include stockholder votes, Nasdaq capital-structure actions, warrants and equity financing arrangements.
CDT Equity (Nasdaq: CDT) agreed to increase its equity stake in agentic AI company Sarborg to 22.7% via a strategic transaction involving pre-funded warrants to purchase up to 12,131,770 CDT common shares, subject to shareholder approval on August 28, 2026.
According to CDT, the move follows Sarborg’s expansion of its Signature Intelligence platform into quantum computing through its SarborgQ division, new IP across pharmaceuticals, agriculture and technology, and a prior third‑party funding round implying a fully diluted valuation of about $638.3 million.
CDT (Nasdaq: CDT) reports that portfolio company Sarborg has filed a new patent application for a large set of field-deployable, two-component combination interventions for sugarcane cultivation, generated using its quantum-enabled PRISM platform.
According to Sarborg, the filing structures 606 field-applicable combinations into six application configurations based on growth stage, delivery route, dose, timing and agronomic target. The combinations were identified using PRISM’s cross-species connectivity engine, powered by SarborgQ, its quantum division. CDT, which acquired 1,020 Sarborg shares on February 20, 2026, representing 20% of Sarborg’s issued share capital at that time, views the patent filing as an important milestone in Sarborg’s Signature Intelligence platform and its extension beyond pharmaceuticals into agriculture.
CDT Equity (Nasdaq: CDT) has approved a 1-for-10 reverse stock split of its common stock to support continued compliance with Nasdaq’s bid-price rule. The split becomes effective on July 17, 2026 at 5:00 p.m. ET, with split-adjusted trading on Nasdaq beginning July 20, 2026 under the existing ticker CDT and a new CUSIP, 20678X601.
At the effective time, every 10 issued and outstanding shares will be combined into one share, with par value unchanged at $0.0001. Outstanding shares are expected to be reduced to approximately 631,077. Equity awards, convertible securities, warrants and plan reserves will be proportionally adjusted. No fractional shares will be issued; affected holders will receive cash instead. Continental Stock Transfer & Trust will act as exchange agent, and most shareholders will not need to take action.
CDT (Nasdaq:CDT) highlighted Sarborg's expansion of its Signature Intelligence platform into quantum-assisted coformer selection via its SarborgQ division. Sarborg is combining proprietary datasets, agentic AI and quantum computing to accelerate solid-form development, support coformer selection and generate new intellectual property across internal assets and future client projects.
CDT (Nasdaq: CDT) highlighted Sarborg’s latest fundraise from a New York-based private investment fund at $125,000 per share, implying a $638.3 million fully diluted valuation.
CDT owns 1,020 Sarborg shares, implying a $127.5 million stake value and added exposure to Sarborg’s new SarborgQ quantum computing division and multi-sector Signature Intelligence platform expansion.
CDT Equity (Nasdaq: CDT) restructured its debt by repaying a $5,737,500 A.G.P. Convertible Loan Note and planning repayment of $555,555.56 under its Ascent Partners Promissory Note. These steps remove over $6.3 million of legacy obligations and simplify its capital structure.
The company also entered a new Loan Agreement with JJ Astor for up to $1,460,000 to fund working capital. About $268,000 has been drawn, with remaining availability subject to conditions. CDT reports its outstanding debt has fallen by over $4 million since early 2025.
CDT Equity (Nasdaq: CDT) reported receipt of a Nasdaq deficiency letter after not timely filing its Form 10-Q for the quarter ended March 31, 2026, as required by Nasdaq Listing Rule 5250(c)(1).
The notice does not immediately affect listing or trading. CDT has until July 20, 2026 to submit a compliance plan and expects to file the Form 10-Q once its review is complete.
CDT Equity (Nasdaq: CDT) received a Canadian patent covering the use of AZD5904 in male infertility, completing protection in key pharmaceutical target markets. The company views this, together with a composition of matter application, as reinforcing its IP position while it advances licensing and strategic partnering discussions.
AZD5904, originally licensed from AstraZeneca, has an extensive clinical safety package and pre-clinical validation in a male infertility market estimated at about USD $4.4 billion annually with no approved drug therapies.
CDT (Nasdaq: CDT) notes Sarborg Limited filed a new Substance of Matter (SOM) patent covering two established cystic fibrosis compounds on May 7, 2026. Sarborg says the patent used its Signature Agent and Multi-Agent platform and was filed in less than three weeks.
CDT holds a 20% stake in Sarborg and says it will evaluate combination opportunities between its assets and the compounds in the filing to expand intellectual property and commercial options.
CDT (Nasdaq: CDT) advanced AZD5904 into the PCT (global patent) phase and has begun partnering discussions to out-license the asset for later-stage development. AZD5904 has clinical safety data from 181 subjects across five Phase 1 studies and currently holds composition-of-matter and method-of-use patents for idiopathic male infertility.
The company cites favourable safety, pre-clinical mechanistic support, and an expanded IP strategy as reasons to pursue global protection and strategic pharma partnerships.